Bio-Rad Introduces Reliance Select cDNA Synthesis Kit, a Reverse Transcription Solution that Efficiently Converts RNA to DNA

Date: 
11/3/20
Reliance Select cDNA Synthesis Kit

HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance Select cDNA Synthesis Kit to help researchers efficiently convert RNA to DNA by reverse transcription.

Converting RNA to DNA is the crucial first step in the study of gene expression and other applications in molecular biology. A more sensitive reverse transcription can lead to the discovery of new biomarkers or a better understanding of the patterns of gene activity that are linked to disease.

"Reliance Select cDNA Synthesis Kit is an important addition to Bio-Rad’s genomics portfolio, providing researchers a way to obtain highly sensitive and reproducible results," said Jennifer Placek, Bio-Rad Product Manager, Life Science Group.

Formulated with a proprietary chimeric enzyme (Reliance RT), this product features:

  • High sensitivity
  • Outstanding reproducibility
  • The ability to create a protocol in minutes
  • A flexible configuration

To learn more, please visit Reliance Select cDNA Synthesis Kit.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Investor Contact:
Kevin Han, Senior Director
Investor Relations
510-741-6777
ir@bio-rad.com

Media Contact:
Tina Cuccia, Manager
Corporate Communications
510-741-6063
tina_cuccia@bio-rad.com